Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas.

Mouse monoclonal antibody MX35 was developed against ovarian cancer. The antibody showed homogeneous reactivity with approximately 90% of human ovarian epithelial cancers and with a limited number of normal tissues by immunohistochemistry. Although mAb MX35 has been used in a number of clinical trials in ovarian cancer, it has been difficult to define the molecular identity of MX35. We report here that mAb MX35 recognizes the sodium-dependent phosphate transport protein 2b (NaPi2b) in human cancer cells. This conclusion is based on several lines of experimental evidence, including 1) the identification of SLC34A2, the gene coding for NaPi2b, by immunoscreening an ovarian cancer cell line cDNA expression library with mAb MX35; 2) mass spectrometry sequencing of peptides obtained by fragmentation from mAb MX35 affinity-purified antigen, which show complete sequence homology to amino acid sequences in NaPi2b; 3) selective down-regulation of SLC34A2 gene expression by RNA interference and the resulting loss of mAb MX35 binding to MX35-expressing human cancer cells; and 4) the demonstration of specific mAb MX35 reactivity with recombinant fusion proteins and with synthetic peptides of the putative largest extracellular loop of NaPi2b. We further show that NaPi2b in cancer cells is expressed on the cell surface as a heavily N-glycosylated protein, with evidence of additional post-translational modifications such as palmitoylation and the formation of disulfide bridges in the major extracellular loop. Membrane transporter molecules, such as NaPi2b, represent a new family of potential cell surface targets for the immunotherapy of cancer with monoclonal antibodies.

[1]  Huqun,et al.  Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis. , 2007, American journal of respiratory and critical care medicine.

[2]  U. Hellman,et al.  Glycoproteome profiling of transforming growth factor‐β (TGFβ) signaling: Nonglycosylated cell death‐inducing DFF‐like effector A inhibits TGFβ1‐dependent apoptosis , 2006, Proteomics.

[3]  H. Murer,et al.  Proximal tubular handling of phosphate: A molecular perspective. , 2006, Kidney international.

[4]  L. Jacobsson,et al.  Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity. , 2006, Nuclear medicine and biology.

[5]  S. Altın,et al.  Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis. , 2006, American journal of human genetics.

[6]  L. Jacobsson,et al.  211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  A. Simpson,et al.  Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[8]  K. Miyamoto,et al.  Inhibitory effect of JTP-59557, a new triazole derivative, on intestinal phosphate transport in vitro and in vivo. , 2005, European journal of pharmacology.

[9]  Krzysztof Fujarewicz,et al.  Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. , 2005, Cancer research.

[10]  H. Murer,et al.  The sodium phosphate cotransporter family SLC34 , 2004, Pflügers Archiv.

[11]  M. Inouye,et al.  Regulation of intestinal NaPi-IIb cotransporter gene expression by estrogen. , 2003, American journal of physiology. Gastrointestinal and liver physiology.

[12]  Kathleen R. Cho,et al.  Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression , 2003, Oncogene.

[13]  D. Horn,et al.  A novel multifunctional labeling reagent for enhanced protein characterization with mass spectrometry. , 2001, Rapid communications in mass spectrometry : RCM.

[14]  B. Yin,et al.  Molecular Cloning of the CA125 Ovarian Cancer Antigen , 2001, The Journal of Biological Chemistry.

[15]  J. Collins,et al.  Molecular cloning, functional characterization, tissue distribution, and chromosomal localization of a human, small intestinal sodium-phosphate (Na+-Pi) transporter (SLC34A2). , 1999, Genomics.

[16]  B. Kaissling,et al.  Expression of type II Na-Picotransporter in alveolar type II cells. , 1999, American journal of physiology. Lung cellular and molecular physiology.

[17]  D. Brooks,et al.  Cloning and functional characterization of a sodium-dependent phosphate transporter expressed in human lung and small intestine. , 1999, Biochemical and biophysical research communications.

[18]  B. Yin,et al.  Initial immunochemical characterization of MX35 ovarian cancer antigen. , 1997, Gynecologic oncology.

[19]  J. Humm,et al.  Distribution of radiolabeled monoclonal antibody MX35 F(ab')2 in tissue samples by storage phosphor screen image analysis: evaluation of antibody localization to micrometastatic disease in epithelial ovarian cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  E C Nice,et al.  Characterization of posttranslational modifications of human A33 antigen, a novel palmitoylated surface glycoprotein of human gastrointestinal epithelium. , 1997, Biochemical and biophysical research communications.

[21]  B. Yin,et al.  Serological and immunochemical analysis of Lewis Y (Ley) blood group antigen expression in epithelial ovarian cancer , 1996, International journal of cancer.

[22]  S. Larson,et al.  Biodistribution and intraoperative evaluation of radiolabeled monoclonal antibody MX35 in patients with epithelial ovarian cancer. , 1993, Gynecologic oncology.

[23]  L. Old,et al.  Mouse monoclonal antibodies to human epithelial differentiation antigens expressed on the surface of ovarian carcinoma ascites cells. , 1987, Cancer research.

[24]  M. Pfreundschuh,et al.  Serological analysis of cell surface antigens of malignant human brain tumors. , 1978, Proceedings of the National Academy of Sciences of the United States of America.